Biophysique et Médecine Nucléaire
Département de Biophysique et Médecine Nucléaire de l'UM1 et du CHU de Montpellier

Articles d’Emmanuel Deshayes

radiotherapie interne vectorisee (travaux cliniques)
  • Walter, T., Jann, H., Ansquer, C., Deshayes, E., Garcia-Carbonero, R., Teule, A., Baum, R. P., Verberne, H. J., Cwikla, J. B., Srirajaskanthan, R., de Mestier, L., Grana, C. M., Buck, A., Horsch, D., Pavel, M., Dierickx, L. O., Michael, M., Strosberg, J., Kollar, A.,…Team, C. I. (2026). [(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. Lancet. https://doi.org/10.1016/S0140-6736(26)00604-5
  • Giraudet, A. L., Kryza, D., Vija, L., Bailly, C., Deshayes, E., Cachin, F., Salaun, P. Y., & Courbon, F. (2026). Radioligand Therapy (RLT) in France. Eur Urol Focus. https://doi.org/10.1016/j.euf.2026.05.013
  • Baudin, E., Durand, A., Beron, A., Smith, D., Déandreis, D., Taieb, D., Ansquer, C., Dierickx, L., Deshayes, E., Hentic, O., Moalla, S., Menu, Y., Lebtahi, R., Assenat, E., Touchefeu, Y., Guimbaud, R., Dahan, L., Lamartina, L., Cheurfa, N.,…Foulon, S. (2026). [(177)Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial. Lancet Oncol, 27(6), 699–710. https://doi.org/10.1016/s1470-2045(26)00108-7
  • Ilonca, A. D., Gudin‐de‐Vallerin, A., Guillemard, S., Eberle, M. C., Briant, J., Guiu, S., Deshayes, E., & Fersing, C. (2025). Gastric Metastases From Invasive Breast Lobular Carcinoma, Identified by [18F]FDG PET/CT, 20 Years After Primary Diagnosis: A Case Report. Clinical Case Reports, 13(9), e70881. https://doi.org/10.1002/ccr3.70881
  • Tran-Gia, J., Cicone, F., Koole, M., Giammarile, F., Gear, J., Deshayes, E., Gabina, P. M., Cremonesi, M., Wadsley, J., Bernhardt, P., Bardies, M., Gnesin, S., Sandstrom, M., Garske-Roman, U., Revheim, M. R., Verburg, F. A., Konijnenberg, M., Krause, B. J., Lassmann, M., & Stokke, C. (2025). Rethinking Dosimetry: A European Perspective. J Nucl Med, 66(9), jnumed.124.269378. https://doi.org/10.2967/jnumed.124.269378
  • Capdevila, J., Pubul, V., Anido, U., Walter, T., Molina-Cerrillo, J., Alonso-Gordoa, T., Garcia-Carbonero, R., San-Roman-Gil, M., Llana, B., Jimenez-Fonseca, P., Benavent Vinuales, M., Ansquer, C., Baudin, E., Lepage, C., Del Olmo-Garcia, M., Ruffinelli, J. C., Beron, A., Haissaguerre, M., Deshayes, E.,…Durand, A. (2025). A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). BMC Cancer, 25(1), 613. https://doi.org/10.1186/s12885-025-13941-3
  • Deshayes, E., Karfis, I., Santoro, L., Mileva, M., Danieli, R., Hebert, K., Maccauro, M., Chiesa, C., & Bardies, M. (2025). Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward! J Nucl Med, 66(6), 983. https://doi.org/10.2967/jnumed.124.268880
  • Hebert, K., Bodin-Cufi, P., Fersing, C., & Deshayes, E. (2024). New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer. Eur Urol Focus, 10(4), 514–517. https://doi.org/10.1016/j.euf.2024.07.016
  • Hebert, K., Santoro, L., Monnier, M., Castan, F., Berkane, I., Assenat, E., Fersing, C., Gelibert, P., Pouget, J. P., Bardies, M., Kotzki, P. O., & Deshayes, E. (2024). Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [(177)Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. J Nucl Med, 65(6), 923–930. https://doi.org/10.2967/jnumed.123.267023
  • Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023). 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic. Pharmaceutics, 15(4), 1051. https://doi:10.3390/pharmaceutics15041051
  • Barakat, A., Santoro, L., Vivien, M., Kotzki, P. O., Deshayes, E., & Khier, S. (2023). Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera((R))) Case. European Journal of Drug Metabolism and Pharmacokinetics, 48(4), 329–339. https://doi.org/10.1007/s13318-023-00829-5
  • Deshayes, E., Fersing, C., Thibault, C., Roumiguie, M., Pourquier, P., & Houede, N. (2023a). Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices. Cancers (Basel), 15(12), 3133. https://doi.org/10.3390/cancers15123133
  • Deshayes, E., Assenat, E., Meignant, L., Bardies, M., Santoro, L., & Gourgou, S. (2022). A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera(R) in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH). BMC Cancer, 22(1), 1346. https://doi.org/10.1186/s12885-022-10443-4
  • Allimant, C., Deshayes, E., Kafrouni, M., Santoro, L., de Verbizier, D., Fourcade, M., Cassinotto, C., Hermida, M., Guillot, C., Mariano-Goulart, D., & Guiu, B. (2021). Hepatobiliary Scintigraphy and Glass (90)Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver. Diagnostics (Basel), 11(6), 931. https://doi.org/10.3390/diagnostics11060931
  • Deshayes, E., Roumiguie, M., Thibault, C., Beuzeboc, P., Cachin, F., Hennequin, C., Huglo, D., Rozet, F., Kassab-Chahmi, D., Rebillard, X., & Houede, N. (2017). Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther, 11, 2643–2651. https://doi.org/10.2147/DDDT.S122417
  • Deshayes, E., Kraeber-Bodere, F., Vuillez, J. P., Bardies, M., Teulon, I., & Pouget, J. P. (2013). Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. Immunotherapy, 5(12), 1283–1286. https://doi.org/10.2217/imt.13.138
methodologie : dosimetrie et radiopharmacie
  • Perrin, O., Benkhoris, S., Vanney, J., Barthelemi, L., Boudousq, V., Deshayes, E., Guisset, C., Soulairol, I., Rubira, L., Fersing, C., & Alize, D. (2026). Expanding (68)Ga radiolabeling capacity: off-label use of PSMA-11 single vial cold kits through aliquoting and dual generator utilization. In EJNMMI Radiopharm Chem. https://doi.org/10.1186/s41181-026-00459-7
  • Fragoso-Negrin, J. A., Vergara-Gil, A., Rahman Hakim, A., Hardiansyah, D., Glatting, G., Ferrer, L., Varmenot, N., Santoro, L., Veloza-Awad, S., Hebert, K., Deshayes, E., & Bardies, M. (2025). OpenDose3D: A Free, Open-Source Clinical Dosimetry Software for Patient-Specific Dosimetry. J Nucl Med. https://doi.org/10.2967/jnumed.125.269539
  • Fragoso-Negrin, J. A., Santoro, L., Hebert, K., Kafrouni, M., Vauclin, S., Kotzki, P. O., Pouget, J. P., Deshayes, E., & Bardies, M. (2025). Methodology for comparing absorbed dose rate calculation algorithms in molecular radiotherapy dosimetry. Phys Med, 133, 104965. https://doi.org/10.1016/j.ejmp.2025.104965
  • Donze, C., Rubira, L., Santoro, L., Viarasakd, M., Kotzki, P. O., Deshayes, E., & Fersing, C. (2024). (177)Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods. Eur J Hosp Pharm, 31(3), 207–211. https://doi.org/10.1136/ejhpharm-2022-003489
  • Souche, C., Fouillet, J., Rubira, L., Donzé, C., Deshayes, E., & Fersing, C. (2024). Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy. International Journal of Molecular Sciences, 25(1), 462.
  • Souche, C., Fouillet, J., Rubira, L., Donze, C., Salle, A., Dromard, Y., Deshayes, E., & Fersing, C. (2024). Towards Optimal Automated (68)Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate. J Labelled Comp Radiopharm, 67(14), 441–453. https://doi.org/10.1002/jlcr.4128
  • Rubira, L., Donze, C., Fouillet, J., Algudo, B., Kotzki, P. O., Deshayes, E., & Fersing, C. (2024). [(68)Ga]Ga-FAPI-46 synthesis on a GAIA(R) module system: Thorough study of the automated radiolabeling reaction conditions. Appl Radiat Isot, 206, 111211. https://doi.org/10.1016/j.apradiso.2024.111211
  • Fouillet, J., Donze, C., Deshayes, E., Santoro, L., Rubira, L., & Fersing, C. (2024). « One Method to Label Them All »: A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617. Curr Radiopharm, 17(3), 285–301. https://doi.org/10.2174/0118744710293461240219111852
  • Donze, C., Rubira, L., Kotzki, P. O., Deshayes, E., & Fersing, C. (2022). Tailored Media-Fill Test Protocols Inspired by (68)Ga Kit-Based Radiopharmaceuticals. PDA J Pharm Sci Technol, 76(5), 416–433. https://doi.org/10.5731/pdajpst.2021.012657
  • Fersing, C., Masurier, N., Rubira, L., Deshayes, E., & Lisowski, V. (2022). AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. Pharmaceuticals (Basel), 15(2), 234. https://doi.org/10.3390/ph15020234
  • Donze, C., Rubira, L., Santoro, L., Kotzki, P. O., Deshayes, E., & Fersing, C. (2022). Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals Administration. Healthcare (Basel), 10(11), 2247. https://doi.org/10.3390/healthcare10112247
  • Fersing, C., Deshayes, E., Langlet, S., Calas, L., Lisowski, V., & Kotzki, P. O. (2021). Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operators. EJNMMI Radiopharm Chem, 6(1), 2. https://doi.org/10.1186/s41181-020-00117-6
  • Santoro, L., Pitalot, L., Trauchessec, D., Mora-Ramirez, E., Kotzki, P. O., Bardies, M., & Deshayes, E. (2021). Clinical implementation of PLANET(R) Dose for dosimetric assessment after [(177)Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit(R) and OLINDA/EXM(R) V1.0. EJNMMI Res, 11(1), 1. https://doi.org/10.1186/s13550-020-00737-8
  • Deshayes, E., Fersing, C., Hebert, K., Bardies, M., Kotzki, P. O., & Santoro, L. (2021). Whole body planar and 3D quantitative imaging after (177)Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First report. Hell J Nucl Med, 24(2), 165–166. https://doi.org/10.1967/s002449912361
  • Mora-Ramirez, E., Santoro, L., Cassol, E., Ocampo-Ramos, J. C., Clayton, N., Kayal, G., Chouaf, S., Trauchessec, D., Pouget, J. P., Kotzki, P. O., Deshayes, E., & Bardies, M. (2020). Comparison of commercial dosimetric software platforms in patients treated with (177) Lu-DOTATATE for peptide receptor radionuclide therapy. Med Phys, 47(9), 4602–4615. https://doi.org/10.1002/mp.14375
  • Santoro, L., Mora-Ramirez, E., Trauchessec, D., Chouaf, S., Eustache, P., Pouget, J.-P., Kotzki, P.-O., Bardiès, M., & Deshayes, E. (2018). Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Research, 8(1), 103. https://doi.org/10.1186/s13550-018-0459-4
recherche pre-clinique et radiobiologie
  • Constanzo, J., Parach, A., David, T., Karam, J., Bruchertseifer, F., Morgenstern, A., Jarlier, M., Bardies, M., Deshayes, E., Gudin-de-Vallerin, A., Boissiere-Michot, F., Lopez-Crapez, E., & Pouget, J. P. (2025). MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy. J Nucl Med, 66(5), 785–792. https://doi.org/10.2967/jnumed.124.268857
  • Mangeat, T., Mairaville, C., Chentouf, M., Neiveyans, M., Pugnière, M., Ngo, G., Denis, V., Catherine, C., Pichard, A., Deshayes, E., Maurel, M., Gracia, M., Bigot, A., Mouly, V., Estaran, S., Chavanieu, A., Martineau, P., & Robert, B. (2025). Generation Using Phage-Display of pH-Dependent Antibodies Against the Tumor-Associated Antigen AXL. Antibodies, 14(4), 83.
  • Constanzo, J., Bouden, Y., Godry, L., Kotzki, P. O., Deshayes, E., & Pouget, J. P. (2023). Immunomodulatory effects of targeted radionuclide therapy. In International Review of Cell and Molecular Biology. Academic Press. https://doi.org/10.1016/bs.ircmb.2023.02.001
  • Mangeat, T., Gracia, M., Pichard, A., Poty, S., Martineau, P., Robert, B., & Deshayes, E. (2023). Fc-engineered monoclonal antibodies to reduce off-target liver uptake. EJNMMI Res, 13(1), 81. https://doi.org/10.1186/s13550-023-01030-0
  • Pouget, J. P., Santoro, L., Piron, B., Paillas, S., Ladjohounlou, R., Pichard, A., Poty, S., Deshayes, E., Constanzo, J., & Bardies, M. (2022). From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group’s experience. Nucl Med Biol, 104-105, 53–64. https://doi.org/10.1016/j.nucmedbio.2021.11.005
  • Ashraf, Y., Mansouri, H., Laurent-Matha, V., Alcaraz, L. B., Roger, P., Guiu, S., Derocq, D., Robin, G., Michaud, H. A., Delpech, H., Jarlier, M., Pugniere, M., Robert, B., Puel, A., Martin, L., Landomiel, F., Bourquard, T., Achour, O., Fruitier-Arnaudin, I.,…Liaudet-Coopman, E. (2019). Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer, 7(1), 29. https://doi.org/10.1186/s40425-019-0498-z
  • Ladjohounlou, R., Lozza, C., Pichard, A., Constanzo, J., Karam, J., Le Fur, P., Deshayes, E., Boudousq, V., Paillas, S., Busson, M., Le Blay, M., Jarlier, M., Marcatili, S., Bardies, M., Bruchertseifer, F., Morgenstern, A., Torgue, J., Navarro-Teulon, I., & Pouget, J. P. (2019). Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. Clin Cancer Res, 25(15), 4775–4790. https://doi.org/10.1158/1078-0432.CCR-18-3295
  • Deshayes, E., Ladjohounlou, R., Le Fur, P., Pichard, A., Lozza, C., Boudousq, V., Sevestre, S., Jarlier, M., Kashani, R., Koch, J., Sosabowski, J., Foster, J., Chouin, N., Bruchertseifer, F., Morgenstern, A., Kotzki, P. O., Navarro-Teulon, I., & Pouget, J. P. (2018). Radiolabeled Antibodies Against Mullerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. J Nucl Med, 59(8), 1234–1242. https://doi.org/10.2967/jnumed.118.208611
  • Estupina, P., Fontayne, A., Barret, J. M., Kersual, N., Dubreuil, O., Le Blay, M., Pichard, A., Jarlier, M., Pugniere, M., Chauvin, M., Chardes, T., Pouget, J. P., Deshayes, E., Rossignol, A., Abache, T., de Romeuf, C., Terrier, A., Verhaeghe, L., Gaucher, C.,…Navarro-Teulon, I. (2017). The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget, 8(23), 37061–37079. https://doi.org/10.18632/oncotarget.15715
  • Paillas, S., Ladjohounlou, R., Lozza, C., Pichard, A., Boudousq, V., Jarlier, M., Sevestre, S., Le Blay, M., Deshayes, E., Sosabowski, J., Chardes, T., Navarro-Teulon, I., Mairs, R. J., & Pouget, J. P. (2016). Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects. Antioxid Redox Signal, 25(8), 467–484. https://doi.org/10.1089/ars.2015.6309
  • Pouget, J. P., Lozza, C., Deshayes, E., Boudousq, V., & Navarro-Teulon, I. (2015). Introduction to radiobiology of targeted radionuclide therapy. Front Med (Lausanne), 2, 12. https://doi.org/10.3389/fmed.2015.00012
  • Buchegger, F., Baechler, S., Bühler, L., Deshayes, E., Gottberg, A., Kosinski, M., Maecke, H. R., Mansi, R., Müller, C., Prior, J. O., Schibli, R., & Stora, T. (2014). 37: 152/161Tb-DOTA-RM6 biodistribution studies in prostate cancer bearing SCID mice and 149Tb sources from CERN-MEDICIS. Radiotherapy and Oncology, 110, S18–S19. https://doi.org/10.1016/s0167-8140(15)34058-5
imagerie scintigraphique et tep en oncologie
  • Assenat, E., Blanc, J.-F., Bouattour, M., Gauthier, L., Deshayes, E., Guillemard, S., Touchefeu, Y., Portales, F., Borg, C., Harguem, L., Guimbaud, R., Ychou, M., & Mazard, T. (2025). Regorafenib plus modified gemcitabine-oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study. (2025-04-01). Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf080
  • Chanchou, M., Mouret-Reynier, M. A., Molnar, I., Deshayes, E., D’Hondt, V., Bourahla, K., Petit, T., Bardet, S., Levy, C., Morel, O., Augereau, P., Rousseau, C., Campone, M., Monteil, J., Venat-Bouvet, L., Faye, A., Benavent, V., & Cachin, F. (2025). (18)F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study. Breast Cancer Res. https://doi.org/10.1186/s13058-025-02156-w
  • Combet-Curt, V., Buchalet, C., Malicot, K. L., Lemanski, C., Deshayes, E., Bonichon-Lamichhane, N., Lievre, A., Huguet, F., Tlili, G., & Vendrely, V. (2024). Prognostic Value of (18)F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE. J Nucl Med, 65(8), 1194–1201. https://doi.org/10.2967/jnumed.124.267626
  • Rouanet, P., Castan, F., Mazard, T., Lemanski, C., Nougaret, S., Deshayes, E., Chalbos, P., Gourgou, S., Taoum, C., & Greccar, P. s. g. (2023). GRECCAR 14 – a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol. Colorectal Dis, 25(10), 2078–2086. https://doi.org/10.1111/codi.16740
  • Galvez, T., Berkane, I., Thézenas, S., Eberlé, M.-C., Flori, N., Guillemard, S., Ilonca, A. D., Santoro, L., Kotzki, P.-O., Senesse, P., & Deshayes, E. (2023). Identification of 18F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer. Nutrients, 15(13), 3042.
  • Meng, J., Deshayes, E., Zhang, L., Shi, W., Zhang, X., Chen, X., Mei, X., Ma, J., Jiang, Y., Wu, J., Shao, Z., Yu, X., Yang, Z., & Guo, X. (2021). Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy. Mol Ther Oncolytics, 23, 412–419. https://doi.org/10.1016/j.omto.2021.10.008
  • Deshayes, E., de Forges, H., Fraisse, J., Eberle, M. C., Guillemard, S., Fallieres, A., Pouget, J. P., Tetreau, R., Kotzki, P. O., Santoro, L., Senesse, P., & Flori, N. (2019). Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study. Clin Nutr, 38(5), 2121–2126. https://doi.org/10.1016/j.clnu.2018.08.033
  • Riou, O., Llacer Moscardo, C., Fenoglietto, P., Deshayes, E., Tetreau, R., Molinier, J., Lenglet, A., Assenat, E., Ychou, M., Guiu, B., Ailleres, N., Bedos, L., & Azria, D. (2017). SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques. Rep Pract Oncol Radiother, 22(2), 103–110. https://doi.org/10.1016/j.rpor.2017.02.006
  • Tetreau, R., Llacer, C., Riou, O., & Deshayes, E. (2017). Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother, 22(2), 170–175. https://doi.org/10.1016/j.rpor.2015.12.004
  • Ricard, F., Cimarelli, S., Deshayes, E., Mognetti, T., Thiesse, P., & Giammarile, F. (2011). Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med, 36(8), 672–677. https://doi.org/10.1097/RLU.0b013e318217ae2e
  • Cimarelli, S., Deshayes, E., Mognetti, T., Biron, P., Desuzinges, C., Rivoire, M., & Giammarile, F. (2009). F-18 FDG PET/CT imaging in a case of primary choriocarcinoma in the retroperitoneum. Clin Nucl Med, 34(7), 449–451. https://doi.org/10.1097/RLU.0b013e3181a7d0cd
imagerie scintigraphique et tep HORS oncologie
  • Dubois, J., Deshayes, E., Kucharczak, F., Cadet, M. M., Zhou, J., Paunet, T., & Fersing, C. (2026). Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective. EJNMMI Radiopharmacy and Chemistry, 11(1). https://doi.org/10.1186/s41181-025-00418-8
  • Guillemard, S., Moulis, L., Ilonca, D., Mestre, S., Deshayes, E., Quéré, I., & Adham, S. (2024). LYMPHOSCORE (Lymphoscintigraphy Scoring Reliability) Reliability of a New Qualitative and Semiquantitative Lymphoscintigraphy Scoring System for Primary Lymphedema. Clin Nucl Med, 49(9), e428–e435. https://doi.org/10.1097/rlu.0000000000005357
  • Bordeau, K., Eberle, M. C., Fabbro, M., Fersing, C., & Deshayes, E. (2022). Lumbosacral Plexus Neurolymphomatosis: A Typical 18FDG PET/CT Pattern to Recognize. Clin Nucl Med, 47(4), 352–353. https://doi.org/10.1097/RLU.0000000000003949
  • Eberle, M. C., Fersing, C., Guillemard, S., Ilonca, D., Guiu, S., & Deshayes, E. (2022). Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean? Diagnostics (Basel), 12(4), 934. https://doi.org/10.3390/diagnostics12040934
  • Nesterov, S. V., Sciagra, R., Orozco, L. E. J., Prior, J. O., Settimo, L., Han, C., Deshayes, E., deKemp, R. A., Ryzhkova, D. V., Gwet, K. L., & Knuuti, J. M. (2022). One-tissue compartment model for myocardial perfusion quantification with N-13 ammonia PET provides matching results: A cross-comparison between Carimas, FlowQuant, and PMOD. J Nucl Cardiol, 29(5), 2543–2550. https://doi.org/10.1007/s12350-021-02741-4
  • Dietz, M., Kamani, C. H., Deshayes, E., Dunet, V., Mitsakis, P., Coukos, G., Nicod Lalonde, M., Schaefer, N., & Prior, J. O. (2021). Imaging angiogenesis in atherosclerosis in large arteries with (68)Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease. EJNMMI Res, 11(1), 71. https://doi.org/10.1186/s13550-021-00815-5
  • Nesterov, S. V., Deshayes, E., Juarez-Orozco, L. E., deKemp, R. A., Sciagra, R., Malaspina, S., Settimo, L., Han, C., Ryzhkova, D. V., Kostina, I. S., Gwet, K. L., Prior, J. O., & Knuuti, J. M. (2022). Myocardial perfusion quantification with Rb-82 PET: good interobserver agreement of Carimas software on global, regional, and segmental levels. Ann Nucl Med, 36(6), 507–514. https://doi.org/10.1007/s12149-022-01729-5
  • Gnesin, S., Mitsakis, P., Cicone, F., Deshayes, E., Dunet, V., Gallino, A. F., Kosinski, M., Baechler, S., Buchegger, F., Viertl, D., & Prior, J. O. (2017). First in-human radiation dosimetry of (68)Ga-NODAGA-RGDyK. EJNMMI Res, 7(1), 43. https://doi.org/10.1186/s13550-017-0288-x
  • Nesterov, S. V., Deshayes, E., Sciagra, R., Settimo, L., Declerck, J. M., Pan, X. B., Yoshinaga, K., Katoh, C., Slomka, P. J., Germano, G., Han, C., Aalto, V., Alessio, A. M., Ficaro, E. P., Lee, B. C., Nekolla, S. G., Gwet, K. L., deKemp, R. A., Klein, R.,…Knuuti, J. M. (2014). Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the RUBY-10 Study. JACC Cardiovasc Imaging, 7(11), 1119–1127. https://doi.org/10.1016/j.jcmg.2014.08.003
  • Deshayes, E., Le Berre, J. P., Jouanneau, E., Vasiljevic, A., Raverot, G., & Seve, P. (2013). 18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease. Clin Nucl Med, 38(1), e50–52. https://doi.org/10.1097/RLU.0b013e31825ae73b
  • Duranton, F., Lacoste, A., Faurous, P., Deshayes, E., Ribstein, J., Avignon, A., Mourad, G., & Argiles, A. (2013). Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism. Clin Kidney J, 6(5), 478–483. https://doi.org/10.1093/ckj/sft092
  • Rahmi, A., Deshayes, E., Maucort-Boulch, D., Varron, L., Grange, J. D., Kodjikian, L., & Seve, P. (2012). Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled fluorodeoxyglucose positron emission tomography. Br J Ophthalmol, 96(1), 99–103. https://doi.org/10.1136/bjo.2010.194514
imagerie scintigraphique de la fonction hepatique
  • Cusumano, C., Deshayes, E., Guiu, B., De Meeus, G., Carrere, S., Bouillin, A., Ilonca, D., Eberle, M. C., Guillemard, S., Fersing, C., Sgarbura, O., & Quenet, F. (2023). Prevention of post-hepatectomy liver failure after major resection of colorectal liver metastases: is hepato-biliary scintigraphy the optimal tool? Ann Transl Med, 11(5), 202. https://doi.org/10.21037/atm-22-3665
  • Guiu, B., Deshayes, E., Panaro, F., Sanglier, F., Cusumano, C., Herrerro, A., Sgarbura, O., Molinari, N., Quenet, F., & Cassinotto, C. (2021). (99m)Tc-mebrofenin hepatobiliary scintigraphy and volume metrics before liver preparation: correlations and discrepancies in non-cirrhotic patients. Ann Transl Med, 9(9), 795. https://doi.org/10.21037/atm-20-7372
  • Memeo, R., Conticchio, M., Deshayes, E., Nadalin, S., Herrero, A., Guiu, B., & Panaro, F. (2021). Optimization of the future remnant liver: review of the current strategies in Europe. Hepatobiliary Surg Nutr, 10(3), 350–363. https://doi.org/10.21037/hbsn-20-394
  • Piron, L., Deshayes, E., Cassinotto, C., Quenet, F., Panaro, F., Hermida, M., Allimant, C., Assenat, E., Pageaux, G. P., Molinari, N., & Guiu, B. (2020). Deportalization, Venous Congestion, Venous Deprivation: Serial Measurements of Volumes and Functions on Morphofunctional 99mTc-Mebrofenin SPECT-CT. Diagnostics (Basel), 11(1), 12. https://doi.org/10.3390/diagnostics11010012
  • Deshayes, E., Piron, L., Bouvier, A., Lapuyade, B., Lermite, E., Vervueren, L., Laurent, C., Pinaquy, J. B., Chevallier, P., Dohan, A., Rode, A., Sengel, C., Guillot, C., Quenet, F., & Guiu, B. (2020). Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colo-rectal liver metastases. BMC Cancer, 20(1), 574. https://doi.org/10.1186/s12885-020-07065-z
  • Guiu, B., Quenet, F., Panaro, F., Piron, L., Cassinotto, C., Herrerro, A., Souche, F. R., Hermida, M., Pierredon-Foulongne, M. A., Belgour, A., Aho-Glele, S., & Deshayes, E. (2020). Liver venous deprivation versus portal vein embolization before major hepatectomy: future liver remnant volumetric and functional changes. Hepatobiliary Surg Nutr, 9(5), 564–576. https://doi.org/10.21037/hbsn.2020.02.06
  • Deshayes, E., Fersing, C., Meunier, L., Quenet, F., & Guiu, B. (2019). Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to Dramatic Underestimation of Liver Function With 99mTc-Mebrofenin Hepatobiliary Scintigraphy. Clin Nucl Med, 45(2), 133–135. https://doi.org/10.1097/rlu.0000000000002861
  • Quenet, F., Pissas, M. H., Gil, H., Roca, L., Carrere, S., Sgarbura, O., Rouanet, P., de Forges, H., Khellaf, L., Deshayes, E., Ychou, M., & Bibeau, F. (2019). Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. Surgery, 165(4), 703–711. https://doi.org/10.1016/j.surg.2018.10.006
  • Panaro, F., Giannone, F., Riviere, B., Sgarbura, O., Cusumano, C., Deshayes, E., Navarro, F., Guiu, B., & Quenet, F. (2019). Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center. Hepatobiliary Surgery and Nutrition, 8(4), 329–337. https://doi.org/10.21037/hbsn.2019.07.06
  • Deshayes, E., Schadde, E., Piron, L., Quenet, F., & Guiu, B. (2017). Extended Liver Venous Deprivation Leads to a Higher Increase in Liver Function that ALPPS in Early Assessment : A comment to « Sparrelid, E. et al. Dynamic Evaluation of Liver Volume and Function in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy. Journal of Gastrointestinal Surgery (2017) ». J Gastrointest Surg, 21(10), 1754–1755. https://doi.org/10.1007/s11605-017-3508-9
  • Guiu, B., Quenet, F., Escal, L., Bibeau, F., Piron, L., Rouanet, P., Fabre, J. M., Jacquet, E., Denys, A., Kotzki, P. O., Verzilli, D., & Deshayes, E. (2017). Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function. Eur Radiol, 27(8), 3343–3352. https://doi.org/10.1007/s00330-017-4744-9
  • Deshayes, E., & Guiu, B. (2016). Liver function: homogenous or not? HPB (Oxford), 18(11), 871. https://doi.org/10.1016/j.hpb.2016.07.017
publications en langue francaise
  • Bailly, C., Giraudet, A. L., Turpin, L., Claudin, M., Tonnelet, D., Habouzit, V., Merlin, C., Deshayes, E., Lussey, C., Robin, P., Deandreis, D., Dekyndt, B., Lamesa, C., Dieudonné, A., Badel, J. N., Courbon, F., & Vija, L. (2026). Radiothérapie interne vectorisée et théranostique en France : recommandations de bonnes pratiques par la Société Française de Médecine Nucléaire. Médecine Nucléaire. https://doi.org/10.1016/j.mednuc.2026.02.001
  • Courbon, F., Kotzki, P. O., Boudousq, V., Fersing, C., Salaun, P. Y., & Deshayes, E. (2025). Lettre à l’éditeur au sujet de l’article « Innovation thérapeutique et enjeux capacitaires en médecine nucléaire : la situation de la RIV en Occitanie » par Guignard et al. (1). Médecine Nucléaire, 49(5), 257–259. https://doi.org/10.1016/j.mednuc.2025.06.008
  • Guillemard, S., Moulis, L., Ilonca, D., Godin, S. M., Deshayes, E., Quere, I., & Adham, S. (2025). LYMPHOSCORE. Nouveau système d’évaluation qualitatif et semi-quantitatif en lymphoscintigraphie des membres inférieurs. Vascular Diseases, 50(1), 35. https://doi.org/10.1016/j.vasdi.2025.01.015 (Original work published LYMPHOSCORE. Nouveau système d’évaluation qualitatif et semi-quantitatif en lymphoscintigraphie des membres inférieurs.)
  • Giraudet, A. L., Hamon, P. A., Coulot, J., Pascal, P., Deshayes, E., Courbon, F., & Salaun, P. Y. (2024a). Étude capacité théranostique 2023–2024 – modélisation sur la base de la RIV-PSMA. Radiothérapie interne vectorisée (RIV), une approche théranostique à laquelle le patient doit avoir accès. Partie I : consolidation nationale. Médecine Nucléaire, 48(4-5), 169–188. https://doi.org/10.1016/j.mednuc.2024.09.001
  • Giraudet, A. L., Hamon, P. A., Coulot, J., Pascal, P., Deshayes, E., Courbon, F., & Salaun, P. Y. (2024b). Étude capacité théranostique 2023–2024 – Modélisation sur la base de la RIV-PSMA. Radiothérapie interne vectorisée (RIV), une approche théranostique à laquelle le patient doit avoir accès. Partie II : analyse approfondie. Médecine Nucléaire, 48(4-5), 189–223. https://doi.org/10.1016/j.mednuc.2024.09.002
  • Assenat, E., & Deshayes, E. (2021). Radiothérapie interne vectorisée et traitement des tumeurs endocrines : historique, modalités pratiques et perspectives. Hépato-Gastro & Oncologie Digestive, 28(4), 520–531. https://doi.org/10.1684/hpg.2021.2153
  • Chanchou, M., Mouret-Reynier, M. A., Cougoul, A., Deshayes, E., D’Hondt, V., Bourahla, K., Petit, T., Bardet, S., Levy, C., Morel, O., Augereau, P., Rousseau, C., Campone, M., Monteil, J., Venat-Bouvet, L., Benavent, V., & Cachin, F. (2020). Value of 18FDG PET for prediction of therapeutic response in HER2+ breast cancer: Interim analysis. Médecine Nucléaire, 44(3), 181–188. https://doi.org/10.1016/j.mednuc.2020.02.003
  • Piron, L., Deshayes, E., Escal, L., Souche, R., Herrero, A., Pierredon-Foulongne, M. A., Assenat, E., le Lam, N., Quenet, F., & Guiu, B. (2017). [Portal vein embolization: Present and future]. Bull Cancer, 104(5), 407–416. https://doi.org/10.1016/j.bulcan.2017.03.009 (Original work published Embolisation portale preoperatoire : present et futur.)
  • Deshayes, E., Collinot, J. A., Dunet, V., Allenbach, G., Mitsakis, P., Muller, O., & Prior, J. O. (2013). L’analyse quantitative en TEP cardiaque. Médecine Nucléaire, 37(5), 181–186. https://doi.org/10.1016/j.mednuc.2013.03.168
  • Collinot, J. A., Deshayes, E., Dunet, V., Iglesias, J. I., Trana, C., Muller, O., & Prior, J. O. (2012). Concordance entre coronarographie et réserve de flux myocardique mesurée par PET/CT cardiaque au rubidium-82. Médecine Nucléaire, 36(4), 163–164. https://doi.org/10.1016/j.mednuc.2012.02.025
  • Deshayes, E., Dunet, V., Rüegg, C., & Prior, J. O. (2012). Imagerie de la néoangiogenèse en médecine nucléaire. Médecine Nucléaire, 36(10), 619–626. https://doi.org/10.1016/j.mednuc.2012.07.010
  • Guigal, V., Pialat, J. B., Vilayphiou, N., Deshayes, E., Rizzo, C., & Gazarian, A. (2010). [Bone quality evaluation in allograft hand transplant]. Chir Main, 29 Suppl 1, S199–213. https://doi.org/10.1016/j.main.2010.10.008 (Original work published Evaluation de la qualite de l’os dans les allogreffes de main.)
  • Audigier, C., Billotey, C., Deshayes, E., Banayan, S., & Janier, M. (2009). Place de la TEP au 18FDG dans la localisation de primitifs néoplasiques. Médecine Nucléaire, 33(8), 508–511. https://doi.org/10.1016/j.mednuc.2009.06.011

Liens vers :